IP Library Patent Application 16238418
Patent Application
App. No. 16/238,418

SYSTEM AND METHOD FOR OPTOGENETIC THERAPY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/238,418
Abstract

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.

Claims (4)

1 . A method for preventing hypertension, comprising:

a. implanting an optical applicator and coupling it to at least one tissue structure such that it can deliver photons to at least one branch of the renal nerve plexus that has been genetically modified to have light sensitive protein;

implanting an implantable light source and intercoupled implantable power supply and coupling each to at least one tissue structure, the implantable light source being configured o deliver photons as an input to the optical applicator when the implantable light source is drawing power from the implantable power supply; and

c. implanting an implantable controller and coupling it to at least one tissue structure, the implantable controller configured o cause the implantable light source to chronically direct enough illumination to the light sensitive protein through the implantable light source and implantable optical applicator to at least partially inhibit action potential transmission within he at least one branch of the renal nerve plexus.

Assignments (1)
SECURITY INTEREST Recorded Nov 3, 2020
From: CIRCUIT THERAPEUTICS, INC.
To: MAGICHEART INVESTMENTS, LLC
Reel/Frame 054291/0504 →